
DivestmentAug 10, 2026, 05:34 PM
Oramed Divests POD™ Tech, Reports $116.5M Net Income
AI Summary
Oramed Pharmaceuticals Inc. reported a significant increase in net income to $116.5 million for the six months ended June 30, 2026, up from $5.6 million in the prior year, primarily driven by a substantial increase in financial income and a gain on the sale of intellectual property. This follows the divestment of its core POD™ technology platform to Lifeward, resulting in Oramed no longer conducting direct clinical development activities. The company is now evaluating strategic alternatives and managing its portfolio of investments, with total assets increasing by 60% to $369.6 million.
Key Highlights
- Divested POD™ technology platform to Lifeward in March 2026.
- Reported net income of $116.5 million for six months ended June 30, 2026, up from $5.6 million YoY.
- Basic EPS for six months ended June 30, 2026, was $2.85, compared to $0.14 YoY.
- Total assets increased 60% to $369.6 million as of June 30, 2026, from $230.9 million.
- Financial income, net, surged to $148.6 million for six months, from $12.8 million YoY.
- Recognized a $5.8 million gain on the sale of intellectual property.
- Research and development expenses decreased to $1.6 million for six months, from $3.2 million YoY.
- Company is evaluating strategic alternatives and managing its investment portfolio.
Price Impact
More from ORMP